AstraZeneca disclaims exec's remarks on outsourcing

Share this article:

AstraZeneca today issued a statement disclaiming remarks made by its global operations chief in a UK newspaper implying plans to outsource all of its supply and manufacturing activities.

David Smith, AstraZeneca's EVP, global operations was quoted by The Times of London in a Monday article as saying, “manufacturing for AstraZeneca is not a core activity… AstraZeneca is about innovation and brand building … There are lots of people and organizations that can manufacture better than we can.”

According to The Times, Smith said AstraZeneca was making it a priority to outsource all of its manufacturing of active pharmaceutical ingredients by 2010.

However, in a statement e-mailed to MM&M by an AstraZeneca spokeswoman today, the drugmaker said “fully outsourcing supply and manufacturing activities, as implied in the article, is not part of the AstraZeneca strategy.”

The statement added that AstraZeneca's global operations “will use outsourcing where there is a sound business case.”

AstraZeneca added that the pretext of The Times interview with Smith was to talk about how the pharmaceutical industry is looking to other industries for a guidance on supply chain practices and philosophies.

The Times article “captured select comments from the interview, specifically relating to outsourcing,” AstraZeneca said.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...